Get the Stockscreener App
2.63
7.72%
-0.22
Indaptus Therapeutics Inc stock is traded at $2.63, with a volume of 496.18K.
It is down -7.72% in the last 24 hours and down -18.07% over the past month.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
See More
Previous Close:
$2.85
Open:
$2.88
24h Volume:
496.18K
Relative Volume:
1.00
Market Cap:
$350.43M
Revenue:
Net Income/Loss:
$-18.86M
P/E Ratio:
-0.1638
EPS:
-16.054
Net Cash Flow:
$-17.68M
1W Performance:
+4.78%
1M Performance:
-18.07%
6M Performance:
-13.49%
1Y Performance:
-23.32%
1-Day Range:
$2.55
$2.92
1-Week Range:
$2.025
$2.92
52-Week Range:
$0.92
$5.9599
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.63 | 350.43M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics Announces Securities Purchase Agreements and Private Placement for $2.135 Million - Quiver Quantitative
Indaptus Therapeutics Extends Timeline for Private Placement Financing - TipRanks
Indaptus Therapeutics Extends $24 Million Private Placement Closing to Oct. 16 - TradingView
Indaptus Therapeutics Announces Private Equity Financing Deal - TipRanks
Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement - marketscreener.com
Form 8K Indaptus Therapeutics Inc For: 10 September By Investing.com - Investing.com South Africa
Form 8K Indaptus Therapeutics Inc For: 10 September By Investing.com - Investing.com Nigeria
Form 8K Indaptus Therapeutics Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Indaptus Therapeutics Inc For: 10 September - Investing.com India
Form 8K Indaptus Therapeutics Inc For: 10 September By Investing.com - Investing.com UK
Indaptus Therapeutics Raises $24 Million in Private Placement of 20.3M Shares - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Indaptus Therapeutics Secures $100 Million At-The-Market Equity Facility - Minichart
Indaptus Therapeutics, Inc. announced that it expects to receive $23.999989 million in funding - marketscreener.com
Indaptus Therapeutics Announces Routine Board Member Resignation - TipRanks
Indaptus Therapeutics, Inc. Announces Resignation of Tim Ruan from Director, Effective September 2, 2026 - marketscreener.com
Indaptus Therapeutics (INDP) updates $100M stock sale plan - Stock Titan
Indaptus Updates ATM Agreement to Expand Capital Flexibility - tipranks.com
Indaptus Therapeutics Launches $100 Million ATM Equity Program With H.C. Wainwright - TradingView
Indaptus sets up $100M at-the-market stock program - Stock Titan
September 2026's Top Stocks by Monthly Momentum - Stock Titan
Indaptus Therapeutics Launches $100M ATM Offering at $1.14 Per Share (NASDAQ: INDP) - Kalkine Media
Indaptus Therapeutics, Inc. SEC Filing (Aug 26, 2026) - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat
Indaptus Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Indaptus Therapeutics Q2 EPS beats estimate as loss narrows - scanx.trade
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot - TipRanks
Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView
Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan
Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative
Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Indaptus Therapeutics (INDP) Falls 14% to $1.02 — Biotech Micro-Cap Tests Critical SupportDescending Triangle - vinanet.vn
Indaptus Therapeutics (INDP) Q4 2025 Earnings: Wider-than-Expected Loss Amid No RevenueReturn On Equity - dars.gov.et
Indaptus Therapeutics (INDP) to Announce Earnings on Monday - MarketBeat
Qinglai Lu Net Worth (2026) - GuruFocus
Indaptus Therapeutics Inc (INDP) Stock News Today - TradingKey
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics (INDP) Slides 10.4% — Approaches Key Support at $1.23Ichimoku Entry - vinanet.vn
Indaptus Therapeutics (INDP) Slides 10.4% as Clinical-Stage Biotech Faces Selling PressureIchimoku Kumo Twist - vinanet.vn
INDP Q4 2025 Earnings: Wider-Than-Expected Loss Sends Shares Down 20.88%EPS Surprise History - vinanet.vn
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Indaptus Therapeutics Inc (INDP) Balance Sheet - TradingKey
Indaptus Therapeutics (INDP) Plunges 21% – Key Support Levels in FocusMFI Divergence - vinanet.vn
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):